LONDON (Reuters) - Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday. In February the company won U.S. Food and Drug Administration (FDA) breakthrough status for new multiple sclerosis drug Ocrevus. That was followed in …
biotechnology
RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference
RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). RetroSense is developing optogenetic approaches to partial vision restoration in retinitis pigmentosa and potentially dry …
Spark Surges in IPO as Prices Fuel Gene Therapy
Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug. The treatments focus on diseases where a single mutation in the genetic code is known to be the cause. Fix or replace the genetic code, and, …